2nd Biologics Manufacturing Japan 2021
The 2nd edition of the Biologics Manufacturing Japan 2021, aims to provide a neutral platform to address the challenges faced in this sector including high costs incurred in the downstream purification of highly complex molecules, purification process development to maximize process economy, difficulties in process development, scale-up and technology transfer for biologics, reduction of Cost-of-Goods for large-scale manufacturing, insights into the regulatory perspective on common pitfalls in analytical and CMC studies, Single-Use Systems in USP & DSP and Cost-Benefit analysis of CMO outsourcing strategies.
Join the conference to interact with key and upcoming entities from Japanese Biologics space include Chugai Pharmaceutical, Kyowa Hakko Kirin, UMN Pharma, Daiichi Sankyo, Daiichi Sankyo, Asahi Glass Co., Astellas Pharma and Fujifilm Holdings Corp among others.
IMAPAC strives to be your one-stop-shop for the biopharma industry’s business intelligence and networking opportunities. Over the past 10 years, IMAPAC has established themselves firmly as a trusted organiser of high quality biopharma B2B confer...